1000 SKOKIE BLVD SUITE 350, WILMETTE, IL
Reports Second Quarter 2026 Financial Results and Provides Business Updates
Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
.2
Shareholder votes
Investor Presentation
Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Reports First Quarter 2026 Financial Results and Provides Business Updates
Q2
Amended Annual Report
Q3
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Amended Notice of Proposed Sale of Securities
S-8 POS
Correspondence
Submission Upload